In the RAISE trial, patients were randomized to receive either IV ganaxolone or a placebo, alongside standard care. One of the trial’s co-primary endpoints—cessation of status epilepticus (SE ...

Marinus sells Ztalmy (ganaxolone), an oral drug designed to reduce seizures in people with CDKL5 deficiency disorder. This is caused by changes in the CDKL5 gene, which encodes a protein that ...